CTOs on the Move

Tricida

www.tricida.com

 
Tricida, Inc., is a pharmaceutical company focused on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a chronic condition commonly caused by CKD that is believed to accelerate the progression of CKD, increase the risk of muscle wasting and cause the loss of bone density. Tricida has successfully completed all of the clinical trials that it planned to complete prior to submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), including a successful 135-subject, ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.tricida.com
  • 7000 Shoreline Court Suite 201
    South San Francisco, CA USA 94080
  • Phone: 415.429.7800

Executives

Name Title Contact Details
Wilhelm Stahl
 Chief Technology Officer Profile

Funding

Tricida raised $55M on 07/26/2016
Tricida raised $57.5M on 11/08/2017
Tricida raised $100M on 03/02/2018

Similar Companies

Pique Therapeutics

Pique Therapeutics is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Affordable Quality Pharmaceuticals

Affordable Quality Pharmaceuticals is a Garden Grove, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mustang Bio

Mustang Bio, Inc., a subsidiary of Fortress Biotech, Inc., is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient`s own immune system to eliminate cancer cells. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and out-licensing or bringing the technologies to market. Mustang has partnered with the City of Hope National Medical Center (“COH”) and Fred Hutchinson Cancer Research Center in the development of proprietary chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies across many cancers. Mustang`s lead programs are in Phase 1 clinical trials at COH: MB-101 for the treatment of brain cancer and MB-102 as a therapeutic agent in acute myeloid leukemia.

Bryn Pharma

Bryn Pharma is a privately held pharmaceutical company based in North Carolina. Primary focus is on the development and commercialization of innovative allergy products for the management of anaphylaxis.

Zenabis Global

Zenabis is a significant Licensed Producer of medical and recreational cannabis, and employs staff coast-to-coast, across facilities in Atholville, New Brunswick; Delta and Langley, British Columbia; and Stellarton, Nova Scotia.